UNSPSC 51434912: Atenolol/chlorthalidone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434912 Atenolol/chlorthalidone is a Commodity code covering pharmaceutical products procured by state and local health agencies, emergency medical services, and multi-state cooperative purchasing alliances for emergency response, institutional patient care, and pharmacy benefit programs. State and local governments use this code to source emergency medications, cardiovascular pharmaceuticals, and generic multi-source drugs through competitive sealed bidding, requests for proposal, and cooperative purchasing vehicles. Soliciting bodies include municipal fire and rescue departments, state health and human services agencies, and multi-state purchasing cooperatives serving hospitals, clinics, and emergency medical systems across multiple jurisdictions. The work encompasses supplying specific quantities of medications with defined National Drug Codes (NDCs), maintaining minimum shelf-life and expiration-date requirements, arranging logistics and delivery within specified timeframes, and providing compliance documentation including Safety Data Sheets, manufacturing certifications, and FDA compliance evidence.

Recent activity spans multiple states and procurement mechanisms. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26P00188) in April 2026 for Advanced Life Support Medications for Tampa Fire Rescue, requesting 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with an estimated contract value of $40,000 and a response deadline of April 8, 2026; the award included a Small Local Business Enterprise sheltered-market 5 percent bid discount not to exceed $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products to be distributed across state and local government facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers with an effective date of July 1, 2026. The Texas Health and Human Services Commission issued an RFI in April 2026 exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler arrangements. Florida, Minnesota, Oregon, and Texas show recent procurement activity under this code.